Chad Costley, MD, MPH, discussed the platform's ability to respond to emerging respiratory diseases and the challenges in advancing mucosal vaccine development for health preparedness.
Chad Costley, MD, MBA
Advertisement
President and Chief Executive Officer of BlueWillow Biologics.
Articles by Chad Costley, MD, MBA
Chad Costley, MD, MBA, provided an update on BlueWillow Biologics' NanoVax intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.
Advertisement
Latest Updated Articles
Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory DiseasesPublished: November 12th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
2
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
3
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
4
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
5
